An analgesia circuit activated by cannabinoids
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Although many anecdotal reports indicate that marijuana and its active constituent, delta-9-tetrahydrocannabinol (delta-9-THC), may reduce pain sensation, studies of humans have produced inconsistent results. In animal studies, the apparent pain-suppressing effects of delta-9-THC and other cannabinoid drugs are confounded by motor deficits. Here we show that a brainstem circuit that contributes to the pain-suppressing effects of morphine is also required for the analgesic effects of cannabinoids. Inactivation of the rostral ventromedial medulla (RVM) prevents the analgesia but not the motor deficits produced by systemically administered cannabinoids. Furthermore, cannabinoids produce analgesia by modulating RVM neuronal activity in a manner similar to, but pharmacologically dissociable from, that of morphine. We also show that endogenous cannabinoids tonically regulate pain thresholds in part through the modulation of RVM neuronal activity. These results show that analgesia produced by cannabinoids and opioids involves similar brainstem circuitry and that cannabinoids are indeed centrally acting analgesics with a new mechanism of action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“cannabinoids produce analgesia either in animal models of pain (both acute pain and tonic pain) or in clinical painful conditions (for reviews see: 161,221), and endogenous cannabinoids are tonically released to participate in the control of basal nociceptive threshold (137).”
From Paracetamol: New Vistas of an Old Drug (2006) · cites this paper as [137]
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin Circuitry
Basbaum, A. I., & Fields, H. L. (1984) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.07.030184.001521 · Cited by 2,687
Self-citationSR141716A, a potent and selective antagonist of the brain cannabinoid receptor
Rinaldi-Carmona, M., Barth, F., Héaulme, M., Shire, D., Calandra, B., Congy, C., Martinez, S., Maruani, J., Néliat, G., Caput, D., et al. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00773-x · Cited by 1,757
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Cadas, H., di Tomaso, E., & Piomelli, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-04-01226.1997 · Cited by 396
The analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518184 · Cited by 378
Research works printed but not linked: 1
- Buxbaum, D., Sanders-Bush, E. & Efron, D. Analgesic activity of tetrahydrocannabinol (THC) in the rat and mouse. Fed. Proc. 28, 735 (1969).
Cited by
Items 101–200 of 411
The Brainstem and Nociceptive Modulation
Heinricher, M. M., & Ingram, S. L. (2008) · The Senses: A Comprehensive Reference · doi:10.1016/b978-012370880-9.00183-3 · Cited by 76
Palazzo, E., De Novellis, V., Petrosino, S., Marabese, I., Vita, D., Giordano, C., Di Marzo, V., Mangoni, G. S., Rossi, F., & Maione, S. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05086.x · Cited by 86
Cannabidiol modulation of oxidative stress and signalling
Pereira, S. R., Hackett, B., O’Driscoll, D. N., Sun, M. C., & Downer, E. J. (2021) · Neuronal Signaling · doi:10.1042/ns20200080 · Cited by 104
Possible mechanisms of cannabinoid-induced antinociception in the spinal cord
Morisset, V., Ahluwalia, J. P., Nagy, I., & Urbán, L. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01309-7 · Cited by 96
Kinsey, S. G., Naidu, P. S., Cravatt, B. F., Dudley, D. T., & Lichtman, A. H. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.022 · Cited by 85
“…et al., 1991), including peripheral terminals of nociceptors (Agarwal et al., 2007), the dorsal horn of the spinal cord, and key brain areas associated with pain (Lichtman et al., 1996; Martin et al., 1995; Meng et al., 1998; Yaksh, 1981), which play a role in cannabinoid-induced antinociception.”
BackgroundMechanism of exercise-induced analgesia: what we can learn from physically active animals
Lesnak, J. B., & Sluka, K. A. (2020) · PAIN Reports · doi:10.1097/pr9.0000000000000850 · Cited by 99
“receptors are located in the PAG, RVM, and dorsal horn of the spinal cord, all of which are locations known to be important for pain modulation.(71,109,157) There are 2 naturally occurring ligands, anandamide (AEA) and 2-arachidonylglycerol (2-AG), that bind to”
BackgroundCannabinoid Analgesia as a Potential New Therapeutic Option in the Treatment of Chronic Pain
Burns, T. L., & Ineck, J. R. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1g217 · Cited by 84
Roche, M., O'Connor, E., Diskin, C., & Finn, D. P. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05861.x · Cited by 83
“, 2006; for recent review, see Chhatwal & Ressler, 2007) and nociception (Calignano et al., 1998; Meng et al., 1998; Strangman et al., 1998; for recent review, see Pertwee, 2001; Finn & Chapman, 2004; Hohmann & Suplita, 2006).”
BackgroundPharmacological treatment of headache using traditional Persian medicine
Gorji, A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00164-0 · Cited by 83
Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis
Schon, F., Hart, P. E., Hodgson, T. L., Pambakian, A. L. M., Ruprah, M., Williamson, E. M., & Kennard, C. (1999) · Neurology · doi:10.1212/wnl.53.9.2209-a · Cited by 83
Differential activation of G‐proteins byμ‐opioid receptor agonists
Saidak, Z., Blake-Palmer, K. G., Hay, D. L., Northup, J. K., & Glass, M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706661 · Cited by 98
“As both these classes of receptors are coupled to G-proteins, including Gai and Gao, these analgesic pathways may not function normally in Ga knockdown mice (Meng et al., 1998; Bie et al., 2003).”
BackgroundSchafer, S. M., Geuter, S., & Wager, T. D. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.008 · Cited by 85
“However, this gating effect may specifically apply to changes in FCA behavior, as injection of an opioid antagonist fails to reduce analgesia following treatment with a cannabinoid agonist (Meng et al., 1998).”
InfluentialEndocannabinoids in pain modulation
Walker, J. M., & Huang, S. M. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0361 · Cited by 91
Synergy between Δ9-tetrahydrocannabinol and morphine in the arthritic rat
Cox, M. L., Haller, V. L., & Welch, S. P. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.04.010 · Cited by 78
“These structures are part of a descending pain control circuit that mediates pain suppressive actions of both opioids and cannabinoids (Basbaum and Fields, 1984; Meng et al., 1998).”
BackgroundThe Role of Cannabinoid Receptors in the Descending Modulation of Pain
Palazzo, E., Luongo, L., de Novellis, V., Rossi, F., & Maione, S. (2010) · Pharmaceuticals · doi:10.3390/ph3082661 · Cited by 92
“thermoceptive stimuli, reversed by selective cannabinoid CB1 receptor antagonists [33,34,42].”
BackgroundSuplita, R. L., Gutierrez, T., Fegley, D., Piomelli, D., & Hohmann, A. G. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.007 · Cited by 80
“The competitive CB1 antagonist/ inverse agonist SR141716A (rimonabant) microinjected into either the dorsolateral PAG (dPAG)(Hohmann et al., 2005) or RVM (Suplita et al., in press) also attenuates SIA.”
BackgroundSupraspinal modulation of pain by cannabinoids: the role of GABA and glutamate
Rea, K., Roche, M., & Finn, D. P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707440 · Cited by 78
“The antinociceptive effect of systemic CB 1 receptor activation was prevented by preinjection of muscimol into the RVM (Meng et al ., 1998), suggesting a role for RVM GABAergic receptors in the mediation of cannabinoid-induced antinociception.”
Analgesic, anti-inflammatory, and antipyretic activity
Vogel, H. G., & Vogel, W. H. (1997) · Springer eBooks · doi:10.1007/978-3-662-03333-3_8 · Cited by 84
Nadal, X., La Porta, C., Andreea Bura, S., & Maldonado, R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.077 · Cited by 76
Cupini, L., Bari, M., Battista, N., Argirò, G., Finazzi‐Agrò, A., Calabresi, P., & Maccarrone, M. (2005) · Cephalalgia · doi:10.1111/j.1468-2982.2005.01031.x · Cited by 82
Klinger-Gratz, P. P., Ralvenius, W. T., Neumann, E., Kato, A., Nyilas, R., Lele, Z., Katona, I., & Zeilhofer, H. U. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.1945-17.2017 · Cited by 74
“…critical role of the RVM in antihyperalgesia by systemic acetaminophen The RVM serves well-established roles in endogenous pain control (Heinricher and Fields, 2013) and as a site of action of centrally acting analgesic drugs, including cannabinoid ligands (Meng et al., 1998; Suplita et al., 2005).”
BackgroundAre oral cannabinoids safe and effective in refractory neuropathic pain?
Attal, N., Brasseur, L., Guirimand, D., Clermond‐Gnamien, S., Atlami, S., & Bouhassira, D. (2004) · European Journal of Pain · doi:10.1016/s1090-3801(03)00084-3 · Cited by 74
“Recently the discovery of the endocannabinoid system (Calignano et al., 1998; Meng et al., 1998; Wilson and Nicoll, 2002) and the identification of two separate cannabinoid receptors (CB1 and CB2) (Matsuda et al.”
Backgroundde Novellis, V., Mariani, L., Palazzo, E., Vita, D., Marabese, I., Scafuro, M. A., Rossi, F., & Maione, S. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.014 · Cited by 73
Martucci, K. T., Eisenach, J. C., Tong, C., & Coghill, R. C. (2012) · Pain · doi:10.1016/j.pain.2012.02.035 · Cited by 78
“Another possibility is that offset analgesia may be supported by nonopioid supraspinal mechanisms because noradrenergic, dopaminergic, serotonergic, and cannabinergic processes are also involved in pain modulation [22,24,42,43,46,61].”
BackgroundCannabis and Cannabinoids: Pharmacology and Rationale for Clinical Use
Pertwee, R. G. (1999) · Complementary Medicine Research · doi:10.1159/000057150 · Cited by 67
Cannabinoids as potential new analgesics
Fuentes, J., Ruiz‐Gayo, M., Manzanares, J., Vela, G., Reche, I., & Corchero, J. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00290-8 · Cited by 72
Craft, R. M., & Leitl, M. D. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.09.004 · Cited by 70
“, Sañudo-Peña and Walker, 1998), and antinociceptive effects are mediated by multiple areas of the central nervous system, including the amygdala, thalamus, periaqueductal gray-rostral ventromedial medulla, and spinal cord (Lichtman et al., 1996; Meng et al., 1998; Martin et al., 1999; Walker et al., 1999).”
BackgroundCannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain
Blanton, H. L., Brelsfoard, J., Deturk, N., Pruitt, K., Narasimhan, M., Morgan, D. J., & Guindon, J. (2019) · Drugs · doi:10.1007/s40265-019-01132-x · Cited by 75
Rea, K., Olango, W. M., Okine, B. N., Madasu, M. K., McGuire, I. C., Coyle, K., Harhen, B., Roche, M., & Finn, D. P. (2014) · Pain · doi:10.1016/j.pain.2013.09.012 · Cited by 69
“Microinjection of cannabinoid compounds directly into the RVM have been shown to modulate neuronal firing in cells of the RVM under conditions of acute [50,54,55,57] and persistent [57] inflammatory pain, as determined by in vivo electrophysiological studies.”
BackgroundUse of Cannabis and Cannabinoids for Treatment of Cancer
Cherkasova, V., Wang, B., Gerasymchuk, M., Fiselier, A., Kovalchuk, O., & Kovalchuk, I. (2022) · Cancers · doi:10.3390/cancers14205142 · Cited by 78
Arachidonylethanolamide Induces Apoptosis of Human Glioma Cells through Vanilloid Receptor-1
Contassot, E., Wilmotte, R., Tenan, M., Belkouch, M.-C., Schnüriger, V., de Tribolet, N., Bourkhardt, K., & Dietrich, P.-Y. (2004) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/63.9.956 · Cited by 67
Finn, D. P., Beckett, S. R. G., Richardson, D., Kendall, D. A., Marsden, C. A., & Chapman, V. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03509.x · Cited by 66
“The ª 2004 Federation of European Neuroscience Societies, European Journal of Neuroscience, 20, 848–852 close association between the opioid and cannabinoid systems and the GABAergic system during nociceptive processing (Meng et al., 1998; Manning et al., 2003) supports the role of such an integrated system in the exp…”
BackgroundInfluentialHemp for Headache: An In-Depth Historical and Scientific Review of Cannabis in Migraine Treatment
Russo, E. (2001) · Journal of Cannabis Therapeutics · doi:10.1300/j175v01n02_04 · Cited by 66
“Meng’s results are discussed above (Meng et al. 1998).”
Basic neuroanatomy and neuropharmacology of cannabinoids
Breivogel, C. S., & Sim‐Selley, L. J. (2009) · International Review of Psychiatry · doi:10.1080/09540260902782760 · Cited by 79
Carter, G. T., Abood, M. E., Aggarwal, S. K., & Weiss, M. D. (2010) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909110369531 · Cited by 65
“Additionally, cannabis may reduce pain sensation, likely through a brain stem circuit that also contributes to the pain-suppressing effects of morphine.(99) Cannabinoids produce analgesia by modulating rostral ventromedial medulla neuronal activity in a manner similar to, but pharmacologically distinct from, that of m…”
BackgroundCannabinoid actions on rat superficial medullary dorsal horn neurons in vitro
Jennings, E. A., Vaughan, C. W., & Christie, M. J. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.00805.x · Cited by 65
“Microinjection of cannabinoids into several brain regions, including the rostral ventromedial medulla (RVM) and periaqueductal grey (PAG), also produces antinociception (Lichtman et al. 1996; Meng et al. 1998; Martin et al. 1999).”
BackgroundMolecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems
Viganò, D., Rubino, T., Vaccani, A., Bianchessi, S., Marmorato, P., Castiglioni, C., & Parolaro, D. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0114-4 · Cited by 65
“…that the brain regions altered are part of a well-established circuit that mediates the descending pain-suppressive actions of opioids and cannabinoids (Walker et al. 1999a; Meng et al. 1998), confirming the neuroanatomical evidence of common opiate/cannabinoid neuronal substrates for analgesia.”
InfluentialMeng, I. D., & Johansen, J. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.10.001 · Cited by 66
“Systemic cannabinoids, like morphine, inhibit on-cell activity, increase off-cell activity, and increase tail flick latencies (Meng et al., 1998).”
BackgroundResultInfluentialSelf-citationMusty, R. E., & Rossi, R. (2001) · Journal of Cannabis Therapeutics · doi:10.1300/j175v01n01_03 · Cited by 65
Marijuana in the management of amyotrophic lateral sclerosis
Carter, G. T., & Rosen, B. S. (2001) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/104990910101800411 · Cited by 67
NSAIDs, Opioids, Cannabinoids and the Control of Pain by the Central Nervous System
Vanegas, H., Vázquez, E., & Tortorici, V. (2010) · Pharmaceuticals · doi:10.3390/ph3051335 · Cited by 69
“Cannabinoids in the RVM, whether exogenous or endogenous, activate offcells and inhibit on-cells, giving rise to “analgesia”, and the RVM is critical for the “analgesic” effects of exogenous cannabinoids [68].”
BackgroundMaldonado, R. J., & Valverde, O. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.001 · Cited by 67
Involvement of the endocannabinoid system in osteoarthritis pain
Porta, C. L., Bura, S. A., Negrete, R., & Maldonado, R. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12468 · Cited by 66
“At the central level, the endocannabinoid system controls nociception through CB1R located at spinal and supraspinal levels (Meng et al., 1998).”
BackgroundHegyi, Z., Kis, G. N., Holló, K., Ledent, C. A., & Antal, M. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06816.x · Cited by 67
“…actions are associated with cannabinoid-induced suppression of noxious stimulus-induced activity of neurons in the spinal cord (Hohmann et al., 1995, 1998, 1999; Meng et al., 1998; Strangman & Walker, 1999; Drew et al., 2000; Harris et al., 2000; Kelly & Chapman, 2001; Pertwee, 2001).”
BackgroundMethodGarzón, J., de la Torre-Madrid, E., Rodríguez-Muñoz, M., Vicente‐Sánchez, A., & Sánchez‐Blázquez, P. (2009) · Molecular Pain · doi:10.1186/1744-8069-5-11 · Cited by 61
“Although cannabinoids act independently of opioids to produce analgesia in rodents, similar brainstem circuitry seems to be involved [21].”
Biological activity of plant extracts: novel analgesic drugs
Calixto, J. Β., Scheidt, C., Otuki, M. F., & Santos, A. R. S. (2001) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.6.2.261 · Cited by 87
Seyrek, M., Kahraman, S., Deveci, M. S., Yeşilyurt, Ö., & Dogrul, A. B. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.039 · Cited by 62
“…gray or rostraventromedial medulla inhibits nociceptive response suggests that one mechanism by which systemically administered cannabinoids produce antinociception is the activation of descending pain inhibitory pathways (Martin et al., 1995, 1998; Meng et al., 1998; Finn et al., 2003).”
Backgroundde Freitas, R. L., Salgado-Rohner, C. J., Hallak, J. E. C., Crippa, J. A. S., & Coimbra, N. C. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000163 · Cited by 62
“The analgesic effect of endocannabinoids requires the rostroventromedial medulla (RVM) circuitry and endocannabinoids modulate the activity of RVM pain-modulating neurons (Meng et al., 1998), suggesting the importance of this neural system in neural bases of pain modulation.”
BackgroundTortorici, V., Morgan, M. M., & Vanegas, H. (2001) · Pain · doi:10.1016/s0304-3959(00)00367-5 · Cited by 62
“Similar effects have been reported following administration of analgesic doses of cannabinoids (Meng et al., 1998), non-steroidal antiin ̄ammatory drugs (Tortorici and Vanegas, 1994, 1995), and GABA antagonists (Moreau and Fields, 1986; Heinricher et al.”
InfluentialKo, M., & Woods, J. H. (1999) · Psychopharmacology · doi:10.1007/s002130050955 · Cited by 58
“It is well documented that cannabinoids produce antinociception at the spinal and supraspinal levels of the central nervous system (Lichtman and Martin 1991; Lichtman et al. 1996; Meng et al. 1998).”
BackgroundHigh Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity
Fitzgibbon, M., Finn, D. P., & Roche, M. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv095 · Cited by 57
Escobar, W., Ramirez, K., Avila, C., Limongi, R., Vanegas, H., & Vázquez, E. (2011) · European Journal of Pain · doi:10.1002/j.1532-2149.2011.00057.x · Cited by 79
“The antinociceptive action of a systemically administered cannabinoid is prevented by inactivation of the RVM with a GABAA agonist (Meng et al., 1998).”
BackgroundCannabis Reduces Opioid Dose in the Treatment of Chronic Non-Cancer Pain
Lynch, M. E., & Clark, A. J. (2003) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(03)00142-8 · Cited by 56
Thompson, Z., Argueta, D. A., Garland, T., & DiPatrizio, N. V. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.11.041 · Cited by 65
Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells
Michalski, C. W., Maier, M., Erkan, M., Sauliunaite, D., Bergmann, F., Pacher, P., Batkai, S., Giese, N. A., Giese, T., Friess, H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001701 · Cited by 54
“Though CB1 receptors constitute the ‘‘main primary antinociceptive targets for systemically- or peripherally-applied cannabinoids in vivo’’ [47], activation of central CB1 receptors also dose-dependently induces side-effects such as hindrance of activity, motor dysfunction, sedation or catalepsy [47–49].”
BackgroundWilson-Poe, A. R., Pocius, E., Herschbach, M., & Morgan, M. M. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.10.002 · Cited by 54
“This antinociception appears to be mediated by inhibition of GABAergic neurons (Meng et al., 1998; Vaughan et al., 1999), as has been reported for morphine antinociception (Heinricher and Tortorici, 1994; Pan et al.”
Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity
Carter, G. T., Flanagan, A. M., Earleywine, M., Abrams, D. I., Aggarwal, S. K., & Grinspoon, L. (2011) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909111402318 · Cited by 65
Khan, M. I., Sobocińska, A., Czarnecka, A., Król, M., Botta, B., & Szczylik, C. (2016) · Current pharmaceutical design · doi:10.2174/1381612822666151211094901 · Cited by 52
“It has potential therapeutic use as an analgesic and against Alzheimer’s disease [29, 31].”
BackgroundHamamoto, D. T., Giridharagopalan, S., & Simone, D. A. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.062 · Cited by 57
“, 2000) and rostral ventromedial medulla (Meng et al., 1998) associated with descending pain modulation (Lichtman and Martin, 1991).”
BackgroundWilson, A. R., Maher, L., & Morgan, M. M. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.038 · Cited by 52
“Although opioids and cannabinoids activate the same descending nociceptive modulatory system (Meng et al., 1998), evidence suggests they trigger this system through separate and distinct mechanisms.”
Zhu, H., Xiang, H.-C., Li, H., Lin, L., Hu, X., Zhang, H., Meng, W., Liu, L., Chen, C., Shu, Y., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00484 · Cited by 61
“It was proposed that opioids and cannabinoids activate the descending pathway by indirectly suppressing the inhibitory influence of local GABAergic interneurons, thereby disinhibiting the antinociceptive pathway of the neuronal output to the spinal cord (Meng et al., 1998).”
BackgroundThe Endocannabinoid System as a Potential Therapeutic Target for Pain Modulation
Ulugöl, A. (2014) · Balkan Medical Journal · doi:10.5152/balkanmedj.2014.13103 · Cited by 64
Yuan, X.-C., Zhu, B., Jing, X.-H., Xiong, L., Wu, C.-H., Gao, F., Li, H., Xiang, H.-C., Zhu, H., Zhou, B., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00112 · Cited by 59
“Previous studies have demonstrated that CB1 receptorsmediated analgesia results from inhibition of GABA release from PAG neurons and subsequent disinhibition of the descending inhibitory pathway involving 5-HT (Meng et al., 1998; Vaughan et al., 2000).”
BackgroundDogrul, A. B., Seyrek, M., Yalçın, B., & Ulugöl, A. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.01.007 · Cited by 61
Vaughan, C. W., Connor, M., Jennings, E. A., Marinelli, S., Allen, R. G., & Christie, M. J. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.00849.x · Cited by 52
“Microinjection of µ-opioids and CB1 cannabinoids but not nociceptin and k-opioids into RVM produces analgesia (Heinricher et al. 1997; Pan et al. 1997; Meng et al. 1998).”
BackgroundKhan, F., & Mehan, A. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.789 · Cited by 53
Pain-facilitating medullary neurons contribute to opioid-induced respiratory depression
Phillips, R. S., Cleary, D. R., Nalwalk, J. W., Arttamangkul, S., Hough, L. B., & Heinricher, M. M. (2012) · Journal of Neurophysiology · doi:10.1152/jn.00563.2012 · Cited by 49
“While the contribution of RVM ON-cells to opioid-induced respiratory depression is novel, the finding is not out of line with a long-standing view of this region as important for coordinating physiological and behavioral aspects of defense in response to both internal and external challenges to homeostasis (Bandler an…”
BackgroundInfluentialCannabinoid receptors and pain
Starowicz, K., Małek, N., & Przewłocka, B. (2013) · Wiley Interdisciplinary Reviews Membrane Transport and Signalling · doi:10.1002/wmts.83 · Cited by 63
Manchikanti, L., Damron, K. S., Beyer, C. D., & Pampati, V. (2003) · Pain Physician · doi:10.36076/ppj.2003/6/281 · Cited by 50
Why Does Increased Exercise Decrease Migraine?
Ahn, A. H. (2013) · Current Pain and Headache Reports · doi:10.1007/s11916-013-0379-y · Cited by 51
Endocannabinoid‐dependent plasticity at spinal nociceptor synapses
Kato, A., Punnakkal, P., Pernía‐Andrade, A. J., von Schoultz, C., Sharopov, S., Nyilas, R., Katona, I., & Zeilhofer, H. U. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2012.234229 · Cited by 54
“…type 1/5 metabotropic glutamate receptor; PB, phosphate buffer; PFA, paraformaldehyde; RIM1alpha, Rab3-interacting molecule 1alpha; sns, sensory neuron specific sodium channel; SP, substance P; STD, short-term depression; TBS, Tris-buffered saline; TENS, transcutaneous electrical nerve stimulation.”
Supraspinal metabotropic glutamate receptors: a target for pain relief and beyond
Palazzo, E., Marabese, I., de Novellis, V., Rossi, F., & Maione, S. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12398 · Cited by 50
“For this reason, ON cells are considered to be ‘pronociceptive’ and OFF cells are considered to be ‘antinociceptive’ (Fields et al., 1983; Heinricher & Tortorici, 1994; Meng et al., 1998; Fields, 2004).”
BackgroundCannabinoids in the descending pain modulatory circuit: Role in inflammation
Bouchet, C. A., & Ingram, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107495 · Cited by 59
Gutierrez, T., Nackley, A. G., Neely, M. H., Freeman, K. G., Edwards, G. L., & Hohmann, A. G. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03324-9 · Cited by 48
Endocannabinoids, hormone-cytokine networks and human fertility
Maccarrone, M., Falciglia, K., Rienzo, M. D., & Finazzi‐Agrò, A. (2002) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.2001.0354 · Cited by 48
Hirakawa, N., Tershner, S., Fields, H. L., & Manning, B. H. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00329-8 · Cited by 45
Self-citationWalker, J. M., Strangman, N. M., & Huang, S. M. (2001) · Pain Research and Management · doi:10.1155/2001/413641 · Cited by 47
Nava, F. A., Carta, G., & Gessa, G. L. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00231-8 · Cited by 46
Williams, J., Haller, V. L., Stevens, D. L., & Welch, S. P. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.12.035 · Cited by 45
Complementary and Alternative Therapies in Amyotrophic Lateral Sclerosis
Bedlack, R., Joyce, N. C., Carter, G. T., Paganoni, S., & Karam, C. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.008 · Cited by 47
Li, M., Suchland, K. L., & Ingram, S. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.1310-16.2016 · Cited by 46
“…inhibition of GABA release disinhibits PAG and RVM output neurons (Heinricher and Ingram, 2008; Lau and Vaughan, 2014) and microinjection of GABAA receptor antagonists in either area results in antinociception (Moreau and Fields, 1986; Heinricher and Tortorici, 1994; Bobeck et al., 2009).”
BackgroundPluskal, T., & Weng, J. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00411g · Cited by 49
Wakley, A. A., & Craft, R. M. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.07.037 · Cited by 48
Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors
Hamann, W., & di Vadi, P. P. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05429-4 · Cited by 45
Magerl, W., Burkart, D., Fernandez, A., Schmidt, L. G., & Treede, R.-D. (2012) · Pain · doi:10.1016/j.pain.2011.11.021 · Cited by 43
“The 2 major stress-related endogenous relief systems, namely, the endogenous opioid and cannabinoid systems act as powerful pain control systems [3,34,55,83,87,88].”
BackgroundRen, K., & Dubner, R. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012370880-9.00192-4 · Cited by 49
Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence
Célèrier, E., Ahdepil, T., Wikander, H., Berrendero, F., Nyberg, F., & Maldonado, R. J. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.017 · Cited by 44
“Thus, cannabinoid actions in the periacqueductal grey and the rostral ventromedial medulla, two important structures for the control of pain, have been reported to involve opioid-independent mechanisms (Meng et al., 1998; Hohmann et al., 2005).”
BackgroundGingold, A. R., & Bergasa, N. V. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00668-4 · Cited by 43
Seeling, W., Kneer, L., Büchele, B., Gschwend, J. E., Maier, L., Nett, C., Simmet, T., Steffen, P., Schneider, M., & Rockemann, M. (2006) · Der Anaesthesist · doi:10.1007/s00101-005-0963-6 · Cited by 42
“Wie aus einem Mosaik von DSE und DSI sowie zusätzlichen postsynaptischen Hemmeffekten die von allen maßgeblichen Autoren als antinozizeptiv beschriebene Gesamtwirkung des CB-Systems zustande kommt [8, 9, 19, 20, 21], ist bis heute noch nicht gänzlich geklärt.”
BackgroundInfluentialScientific Validation of Cannabidiol for Management of Dog and Cat Diseases
Alvarenga, I. C., Panickar, K. S., Hess, H., & McGrath, S. (2023) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-081122-070236 · Cited by 60
Legalization of Medical Marijuana and Incidence of Opioid Mortality
Hayes, M. J., & Brown, M. S. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.2716 · Cited by 44
The medial temporal lobe in nociception: a meta-analytic and functional connectivity study
Ayoub, L. J., Barnett, A. J., Leboucher, A., Golosky, M., McAndrews, M. P., Seminowicz, D. A., & Moayedi, M. (2019) · Pain · doi:10.1097/j.pain.0000000000001519 · Cited by 46
Hald, A., Ding, M. L., Egerod, K. L., Hansen, R. B., KONRADSEN, D., JORGENSEN, S., Atalay, B., Nasser, A., Bjerrum, O. J., & Heegaard, A. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.04.021 · Cited by 45
Functional imaging and the neural systems of chronic pain
Mackey, S., & Maeda, F. (2004) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2004.03.001 · Cited by 44
Bulbospinal nociceptive ON and OFF cells related neural circuits and transmitters
Peng, B., Jiao, Y., Zhang, Y., Li, S., Chen, S., Xu, S., Gao, P., Fan, Y., & Yu, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1159753 · Cited by 50
“, 2010), and cannabinoids (Meng et al., 1998), which will also be discussed in this review.”
BackgroundCannabis for Chronic Pain: Case Series and Implications for Clinicians
Ware, M. A., Gamsa, A., Persson, J., & Fitzcharles, M.-A. (2002) · Pain Research and Management · doi:10.1155/2002/380509 · Cited by 38
“The recent discovery of specific cannabinoid receptors (2,3) and endogenous cannabinoid ligands (4,5) that play an important role in pain transmission (6) has renewed interest in natural and synthetic cannabinoids as therapeutic agents.”
BackgroundNaderi, N., Shafaghi, B., Khodayar, M. J., & Zarindast, M. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.03.037 · Cited by 37
Hjørnevik, T., Jacobsen, L. M., Qu, H., Bjaalie, J. G., Gjerstad, J., & Willoch, F. (2008) · Pain · doi:10.1016/j.pain.2008.09.029 · Cited by 44
“For instance, local activation of the opioid or cannabinoid receptors in the amygdala can inhibit nociceptive spinal reflexes [20]; (4) unilateral inactivation of the amygdala (with the GABAA receptor agonist muscimol) reduces the ability of morphine to suppress prolonged formalin-induced pain behavior derived from th…”
BackgroundCannabinoids in pain and inflammation
Mbvundula, E. C., Rainsford, K. D., & Bunning, R. A. D. (2004) · Inflammopharmacology · doi:10.1163/1568560041352275 · Cited by 41
“…produce analgesia by modulating the RVM neuronal activity in a similar manner to, but pharmacologically dissociable from, that of opioids (Meng et al., 1998), and Hamann and di Vadi (1999) also demonstrated that cannabinoids exert their analgesic effects independently of opioid receptors…”
Maccarrone, M., Salvati, S., Bari, M., & Finazzi‐Agrò, A. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3869 · Cited by 35
Metadata
- Authors
- Meng, I. D., Manning, B. H., Martin, W. J., & Fields, H. L.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Meng, Ian D.
- Venue
- Nature
- Published
- 1998-09
- Volume
- 395
- Issue
- 6700
- Pages
- 381-383
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1645449597
- Cited by
- 411
- References
- 30
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 8 · 2022: 8 · 2021: 18 · 2020: 13 · 2019: 11 · 2018: 5 · 2017: 11 · 2016: 12 · 2015: 10 · 2014: 13 · 2013: 12 · 2012: 15
- FWCI
- 17.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cannabinoid analgesia, delta-9-tetrahydrocannabinol, rostral ventromedial medulla, morphine analgesia, endocannabinoids, motor impairment, opioid analgesia
- MeSH terms
- Rimonabant, Analgesia, Animals, Cannabinoids, Male, Medulla Oblongata, Morphine, Morpholines, Motor Activity, Muscimol, Naphthalenes, Neural Pathways, Neurons, Piperidines, Pyrazoles, Receptors, Drug, Rats, Sprague-Dawley, Analgesics, Non-Narcotic, GABA Agonists, Receptors, Cannabinoid, Benzoxazines, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.